Table 3

Comparison of GLP-1 analogues in DPP-4 inhibitors- data from fully published RCTs [33-35,37].

Study

The 1860- Lira DPP-4 study (52 weeks)

DURATION 2 (26 weeks) - Add on therapy to Metformin

DURATION 4 (26 weeks) - Monotherapy


Agent

Liraglutide .8 mg/day

Liraglutide1.2 mg/day

Sitagliptin100 mg/day

Exenatide QW2 mg/weekly

Sitagliptin100 mg/day

Exenatide QW2 mg/weekly

Sitagliptin100 mg/day


Number of patients

225

221

219

160

166

248

163

Mean baseline HbA1c (%)

8.4 (0.8)

8.4 (0.7)

8.5 (0.7)

8.6 (1.2)

8.5 (1.2)

8.4-8.6

8.4-8.6

Change in HbA1c (%)

-1.51

-1.29

-0.88

-1.5

-0.9

-1.53

-1.15

(P =<0.001)

Mean treatment difference in HbA1c with DPP-4 inhibitor

-0.63

(P <0.0001)

-0.4

(P <0.0001)

-

-0.6

(P <0.0001)

-

-

-

Mean baseline FPG

(mmol/L)

10.1 (2.4)

9.9(2.4)

10.0 (2.0)

9.2(2.9)

9.1(2.5)

9.7 to 9.9

9.7 to 9.9

Change in FPG

(mmol/L)

-2.04

-1.71

-0.59

-1.8

-0.9

-2.3

-1.1

(P =<0.001)

Mean treatment difference in FPG with DPP-4 inhibitor

-1.45

(P <0.0001)

-1.13

(P <0.0001)

-

-0.9

(P <0.0001)

-

-

-

Baseline weight (Kg)

93.7(18.4)

94.6(18.1)

93.1(18.9)

89(20)

87(20)

85.9 to 88.6

85.9 to 88.6

Change in weight (Kg)

-3.68

-2.78

-1.16

-2.3

-0.8

-2.0

-0.8

(P <0.001)

Mean treatment differences in weight with DPP-4 inhibitor

-2.53

(P <0.0001)

-1.62

(P <0.0001)

-

-1.5

(P <0.0001)

-

-

-

Incidence of hypoglycemia

0.143episodes/

patient/year

0.154

episodes/

patient/year

0.137

episodes/

patient/year

1%

3%

5.2%

3.1%

Nausea Number (%)

60 (27.5)

40 (21.7)

12 (5.5)

38 (24)

16 (10)

11.3%

3.7%

Diarrhea Number (%)

27 (12.4)

20 (9)

14 (6.4)

29 (18)

16 (10)

10.9%

5.5%


DDP-4, dipeptidyl peptidase 4; FPG, fasting plasma glucose; GLP-1, glucagon-like peptide 1; HbA1c, hemoglobulin A1c

Nisal et al. BMC Medicine 2012 10:152   doi:10.1186/1741-7015-10-152

Open Data